These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 15256461

  • 1. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 2. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 3. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 4. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF, Erff M, Ashkenazi A.
    Clin Cancer Res; 2001 May 15; 7(5):1362-9. PubMed ID: 11350907
    [Abstract] [Full Text] [Related]

  • 5. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 7. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
    Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E.
    Drug Metab Dispos; 2004 Nov 01; 32(11):1230-8. PubMed ID: 15282212
    [Abstract] [Full Text] [Related]

  • 8. Safety and antitumor activity of recombinant soluble Apo2 ligand.
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.
    J Clin Invest; 1999 Jul 01; 104(2):155-62. PubMed ID: 10411544
    [Abstract] [Full Text] [Related]

  • 9. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 10. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA.
    J Pharmacol Exp Ther; 2001 Oct 15; 299(1):31-8. PubMed ID: 11561060
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S, Schüller A, Frese-Schaper M, Gugger M, Schmid RA.
    Anticancer Res; 2009 Aug 15; 29(8):2905-11. PubMed ID: 19661294
    [Abstract] [Full Text] [Related]

  • 12. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
    Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA.
    Immunol Invest; 2006 Aug 15; 35(3-4):279-96. PubMed ID: 16916755
    [Abstract] [Full Text] [Related]

  • 13. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 15; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 14. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong S.
    Cancer Res; 2003 Feb 01; 63(3):621-6. PubMed ID: 12566305
    [Abstract] [Full Text] [Related]

  • 15. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S.
    Clin Cancer Res; 2003 Aug 15; 9(9):3397-405. PubMed ID: 12960128
    [Abstract] [Full Text] [Related]

  • 16. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y, Harada K, Ferdous T, Yoshida H.
    Anticancer Res; 2007 Aug 15; 27(4B):2365-75. PubMed ID: 17695527
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F, Wang AP, Yang SF.
    Acta Pharmacol Sin; 2005 Nov 15; 26(11):1373-81. PubMed ID: 16225761
    [Abstract] [Full Text] [Related]

  • 18. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ.
    Cancer Res; 2000 Feb 15; 60(4):847-53. PubMed ID: 10706092
    [Abstract] [Full Text] [Related]

  • 19. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S.
    Cancer Res; 2006 Apr 15; 66(8):4309-18. PubMed ID: 16618756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.